{"id":6025,"date":"2026-04-13T08:32:37","date_gmt":"2026-04-13T15:32:37","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=6025"},"modified":"2026-04-13T08:32:37","modified_gmt":"2026-04-13T15:32:37","slug":"reset-t1d","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/reset-t1d\/","title":{"rendered":"Reset T1D"},"content":{"rendered":"
<\/div>\n

TrialNet is studying rezpegaldesleukin to see if it can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance.<\/p>\n

Rezpegaldesleukin is already being studied in people with other autoimmune diseases like psoriasis and eczema. This is the first time it is being studied in people with TID.<\/p>\n

Like all clinical research, there are benefits and risks to participating in this study. Before you join the study, a TrialNet team member will explain all potential benefits and risks and answer your questions.<\/p>\n

Participant Eligibility<\/h3>\n

-Newly diagnosed with T1D (in the past 3 months)
\n-Ages 18 to 45<\/p>\n

Your screening tests show:
\n-1 or more diabetes-related autoantibody
\n-Detectable C-peptide during a mixed meal tolerance test (MMTT)<\/p>\n

A research team member will go over the full list of eligibility criteria with you before your screening visit.<\/p>\n

Contact<\/h3>\n

the Outreach Team
\n(800) 888-4187<\/p>\n

<\/p>\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nRezpegaldesleukin for Newly Diagnosed T1D Study (RESET T1D)
\n<\/span><\/p>\n

Study ID:<\/strong> TN36<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT07142252<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 03\/25\/2026<\/div>\n
End Date:<\/strong> 05\/25\/2028<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nKurt Griffin, MD
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

Benaroya Research Institute<\/h4>\n

1201 9th Ave
\nSeattle, Washington 98101<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TrialNet is studying rezpegaldesleukin to see if it can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance. Rezpegaldesleukin is already being studied in people with other autoimmune diseases like…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[323],"class_list":["post-6025","post","type-post","status-publish","format-standard","hentry","category-diabetes","tag-type-1-diabetes"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=6025"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6025\/revisions"}],"predecessor-version":[{"id":6027,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6025\/revisions\/6027"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=6025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=6025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=6025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}